

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
08/808,629	02/28/1997	JAYANTA ROY-CHOWDHURY	ENZ-55	6556	
28169	7590 01/15/2002				
ENZO THEF	RAPEUTICS, INC.		EXAMI	EXAMINER	
C/O ENZO BIOCHEM INC. 527 MADISON AVENUE 9TH FLOOR NEW YORK, NY 10022			SCHWADRON, RONALD B	RONALD B	
			ART UNIT	PAPER NUMBER	
		•	1644		
			DATE MAILED: 01/15/2002	2	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 08/808,629

Applicant(s)

Examiner

Roy-Chowdhury et al.

1644

Art Unit

Ron Schwadron

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -- Period for Reply

THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.				
af - If the	ter SIX (6) MONTHS from the mailing date of this communic	FR 1.136 (a). In no event, however, may a reply be timely filed cation. s, a reply within the statutory minimum of thirty (30) days will			
- If NO		period will apply and will expire SIX (6) MONTHS from the mailing date of this			
- Failui - Any i	re to reply within the set or extended period for reply will, b	y statute, cause the application to become ABANDONED (35 U.S.C. § 133). e mailing date of this communication, even if timely filed, may reduce any			
Status	•				
1) 🗆	Responsive to communication(s) filed on	·			
2a) 🗌	This action is FINAL . 2b) X This ac	tion is non-final.			
3) 🗌	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.				
Disposi	tion of Claims				
4) 💢	Claim(s) <u>121-125</u>	is/are pending in the application.			
4	la) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗌	Claim(s)	is/are allowed.			
6) 💢	Claim(s) <u>121-125</u>	is/are rejected.			
7) 🗌	Claim(s)	is/are objected to.			
8) 🗆		are subject to restriction and/or election requirement.			
Applica	ition Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are objected to by the Examiner.				
11)	The proposed drawing correction filed on	is: a) □ approved b) □ disapproved.			
12)	The oath or declaration is objected to by the Exam	iner.			
Priority	under 35 U.S.C. § 119				
	Acknowledgement is made of a claim for foreign p				
a).L					
1. Certified copies of the priority documents have been received.					
	2. ☐ Certified copies of the priority documents have				
	3. ☐ Copies of the certified copies of the priority d application from the International Bure see the attached detailed Office action for a list of th	ocuments have been received in this National Stage au (PCT Rule 17.2(a)). e certified copies not received.			
14)	Acknowledgement is made of a claim for domestic	ı			
Attachme	ent(s)				
15) 💢 No	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).			
	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)			
17) 🔲 Inf	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:			

Serial No. 08/808629 Art Unit 1644

- 1. Applicant's election of Group I, claims 121-148 in Paper No. 10 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (M.P.E.P. § 818.03(a)).
- 2. Claims 149-155 are withdrawn from further consideration by the examiner, 37 C.F.R. § 1.142(b) as being drawn to a nonelected invention. Election was made **without** traverse in Paper No. 10.
- 3. Claims 121-125 are under consideration. Claims 126-155 were canceled in page 2 of Paper No. 10.
- 4. Regarding the term "selective immune down regulation" (SIDR), said phrase is interpreted as per the definition of said term on paragraph one, page 7 of the instant application.
- 5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Serial No. 08/808629 Art Unit 1644

6. Claims 121-124 are rejected under 35 U.S.C. 102(e) as being anticipated by Selawry (US Patent 5,849,285).

Selawry teaches a method wherein systemic tolerance is induced to transplant antigens in a recipient, followed by administration of a graft containing the tolerized antigens (see column 8, last paragraph continued on column 9 and column 9, first complete paragraph). Selawry teach that the transplanted graft is bone marrow (see column 8, last paragraph continued on column 9). The method of Selawry induces systemic tolerance and it is an inherent property of said method that the tolerance is antigen specific (eg. said method induces SIDR). Selawry teaches that the method can be combined with treatment with other immune modulating agents (see column 9, penultimate paragraph).

7. Claims 121,122 are rejected under 35 U.S.C. 102(b) as being anticipated by Pearson et al.

Pearson et al. teaches a method wherein systemic tolerance is induced to transplant antigens (DST) in a recipient, followed by administration of a graft containing the tolerized antigens (see page 565). The method of Pearson et al. induces tolerance to a transplanted graft, while the recipient can still reject a graft from a third party donor (eg. a donor containing MHC antigens to which tolerance has not been induced, see page 565, second column section *Specificity of the tolerant State*).

8. Claim 125 is rejected under 35 U.S.C. 102(b) as being anticipated by McMenamin et al.

McMenamin et al. teach induction of antigen specific tolerance to OVA in a recipient (see Figure 1 and page 1869, second column and third column). McMenamin et al. teach that immune cells from said tolerized recipient can be transferred to a second animal and induce tolerance to OVA in said recipient of the tolerized immune cells (see Figure 1).

- 9. No claim is allowed.
- 10. Papers related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the

Serial No. 08/808629 Art Unit 1644

Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Group 1600 at (703) 308-4242.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-4680. The examiner can normally be reached Tuesday through Friday from 8:30 to 6:00. The examiner can also be reached on alternative Mondays. A message may be left on the examiners voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ms. Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

RSI

RONALD B. SCHWADRON PRIMARY EXAMINER GROUP 1800 (600

Ron Schwadron, Ph.D. Primary Examiner Art Unit 1644 June 12, 2001

. --

·· –